Preveceutical Stock Price, News & Analysis

BioGene Therapeutics Inc., a subsidiary of PreveCeutical Medical Inc. (OTCQB: PRVCF), has appointed Dr. Francis Tavares as Chief Technology Officer effective August 19, 2025. Dr. Tavares brings 30 years of experience in drug discovery and development, previously serving as President and CEO of ChemoGenics BioPharma and Group Manager at GlaxoSmithKline.

His notable achievements include leading the development of Trilaciclib and completing Phase 3 trials of Lerociclib, a CDK4/6 inhibitor. Dr. Tavares holds a PhD in Organic Chemistry and has extensive experience in developing small-molecule inhibitors, having championed over 15 metabolic targets throughout his career.

PreveCeutical Medical (OTCQB: PRVCF) has announced the appointment of Dr. Kamal Albarazanji as Senior Director of Metabolic Research at its subsidiary BioGene Therapeutics, effective August 18, 2025. Dr. Albarazanji brings extensive experience in metabolic research, having previously served as a Senior Scientist in Cardiovascular & Metabolic Diseases.

Dr. Albarazanji's background includes significant work at SmithKline Beecham (now GSK) on various therapeutic programs, including renin inhibitors and insulin sensitizers. He holds multiple patents and has authored over 20 peer-reviewed publications in prestigious journals. His expertise spans in vivo pharmacology, target validation, and translational research, with particular focus on metabolic diseases, obesity, and diabetes treatments.

PreveCeutical Medical (OTCQB: PRVCF) has rescheduled its annual general and special meeting from August 15 to September 5, 2025. At the meeting, shareholders will vote on key matters including director elections and the appointment of Davidson & Company LLP as auditors.

A significant proposal involves the distribution of up to 12 million common shares of BioGene Therapeutics to PreveCeutical shareholders through a plan of arrangement. This strategic move will result in shareholders owning stakes in both companies: BioGene, focusing on Dual Gene Therapy development, and PreveCeutical, continuing its work on preventive and curative therapies using organic products.

PreveCeutical Medical Inc. (OTCQB: PRVCF) has appointed Dr. Francis Tavares as Chief Technology Officer, effective June 27, 2025. Dr. Tavares brings over three decades of experience in organic and medical chemistry, and drug discovery to the company.

Dr. Tavares most recently served as President and CEO of ChemoGenics BioPharma, where he led drug discovery initiatives resulting in the commercialization of Trilaciclib and successful Phase 3 clinical trials of Lerociclib, a CDK4/6 inhibitor. His career includes significant achievements at GlaxoSmithKline, where he received the Excellence in Science Award in 2004, and the successful establishment of ChemoGenics BioPharma.

The appointment strengthens PreveCeutical's leadership team as the company continues its development of preventive and curative therapies using organic and nature-identical products.

PreveCeutical Medical (OTCQB: PRVCF) has scheduled its annual general and special meeting for August 15, 2025. Shareholders will vote on director elections, auditor appointments, and notably, a plan to distribute up to 12 million common shares of BioGene Therapeutics to PreveCeutical shareholders.

The arrangement will result in shareholders owning stakes in two separate companies: BioGene, focusing on Dual Gene Therapy program development, and PreveCeutical, continuing its focus on preventive and curative therapies using organic products. This strategic separation aims to expand both companies' shareholder bases and improve access to capital for research and development.

PreveCeutical Medical has appointed Dr. Deepak Sampath as a corporate advisor effective May 30, 2025. Dr. Sampath brings over 25 years of expertise in molecular and cellular biology, pharmacology, and drug development. His notable achievements include contributing to the FDA approval of venetoclax for CLL/SLL treatment. Currently serving as Senior VP and Head of Research at Ultragenyx, he leads multidisciplinary functions in various scientific fields. Dr. Sampath has published 108 peer-reviewed articles and is named on 21 issued patents and 11 patent applications. His expertise spans protein biologics, nucleic acids, and gene therapies for rare genetic conditions.

PreveCeutical Medical (OTCQB: PRVCF) has appointed Stephen Glover as Corporate Advisor, effective May 24, 2025. The health sciences company, which focuses on developing innovative preventive and curative therapies using organic and nature-identical products, expects to benefit from Glover's extensive experience in biopharma, corporate strategy, commercialization, and financial management. CEO Stephen Van Deventer emphasized Glover's proven leadership and track record in building and transforming organizations as key assets for advancing PreveCeutical's therapeutic development mission.

PreveCeutical Medical Inc. (PRVCF) has announced the launch of a new website for its majority-owned subsidiary, BioGene Therapeutics Inc., a Texas-based life sciences company. The website aims to showcase BioGene's research and development initiatives, particularly focusing on metabolic health and gene-based treatments.

Through its wholly-owned subsidiary BioGene Australia, the company is conducting research on GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies targeting the global diabetes and obesity crisis. The website launch is part of BioGene's growth strategy to enhance stakeholder communication and industry engagement.

PreveCeutical Medical Inc. (PRVCF) has announced a new program to develop their Nose to Brain (N2B) Sol-Gel platform for delivering Dopamine and L-Dopa directly to the brain for Parkinson's disease treatment. The technology is designed to bypass the Blood Brain Barrier (BBB), which could potentially improve drug bioavailability while reducing side effects associated with current delivery methods.

The company expects this approach to enhance safety and effectiveness by avoiding systemic exposure and requiring lower therapeutic doses through direct brain targeting. The N2B platform's ability to bypass other body compartments could lead to reduced drug dosages and improved patient compliance.

PreveCeutical plans to demonstrate proof of concept in preclinical models before seeking partnerships with organizations specializing in Parkinson's disease.